

Open camera or QR reader and
scan code to access this article
and other resources online.



Antibiotic Use in a Neonatal Intensive Care Unit Practicing Integrative Medicine—A Retrospective Analysis

Jan Vagedes, MD, MA,^{1–3,*} Benedikt M. Huber, MD,^{4,5,*} Mohammad Oli Al Islam, MSc,¹
Katrin Vagedes, DVM,¹ Matthias Kohl, PhD,⁶ and Tido von Schoen-Angerer, MD, MPH^{1,4,5}

Abstract

Background: Antibiotic use in neonatal intensive care units (NICUs) remains high. Low antibiotic prescribing has been documented among physicians trained in complementary medicine. This study sought to identify if an NICU integrating complementary medicine has low antibiotic prescribing.

Methods: We conducted a retrospective analysis at the level-2 NICU of the Filderklinik, an integrative medicine hospital in Southern Germany, to compare antibiotic use locally and internationally; to compare neonates with suspected infection, managed with and without antibiotics; and to describe use and safety of complementary medicinal products.

Results: Among 7778 live births, 1086 neonates were hospitalized between 2014 and 2017. Two hundred forty-six were diagnosed with suspected or confirmed infection, their median gestational age was 40.3 weeks (range 29–42), 3.25% had a birthweight <2500 g, 176 were treated with antibiotics for a median duration of 4 days, 6 had culture-proven infection (0.77 per 1000 live births), and 2.26% of live births were started on antibiotics. A total of 866 antibiotic treatment days corresponded to 111 antibiotic days per 1000 live births and 8.8 antibiotic days per 100 hospital days. Neonates managed with antibiotics more often had fever and abnormal laboratory parameters than those managed without. Complementary medicinal products comprising 71 different natural substances were used, no side effect or adverse event were described. A subanalysis using the inclusion criteria of a recent analysis of 13 networks in Europe, North America, and Australia confirmed this cohort to be among the lowest prescribing networks.

Conclusions: Antibiotic use was low in this NICU in both local and international comparison, while the disease burden was in the mid-range, confirming an association between integrative medicine practice and low antibiotic prescribing in newborns. Complementary medicinal products were widely used and well tolerated.

Clinical Trial Registration number: NCT04893343.

¹ARCIM Institute, Filderstadt, Germany.

²Department of Pediatrics, Filderklinik, Filderstadt, Germany.

³Department of Neonatology, University Hospital Tübingen, Tübingen, Germany.

⁴Center for Integrative Pediatrics, Fribourg Cantonal Hospital, Fribourg, Switzerland.

⁵Department of Community Health, Fribourg University, Fribourg, Switzerland.

⁶Institute of Precision Medicine, University Furtwangen, Furtwangen, Germany.

*These two authors contributed equally to this work.

Keywords: neonatal intensive care, neonatal infection, neonatal sepsis, integrative medicine, antibiotic use rate, antibiotic stewardship, anthroposophic medicine

Introduction

THE USE OF ANTIBIOTICS IN neonatal intensive care units (NICUs) is under scrutiny not only because of rising antibiotic resistance in the neonatal population¹ but also for the short- and long-term negative health effects of early antibiotic use,² such as necrotizing enterocolitis,³ bronchopulmonary dysplasia,⁴ invasive candidiasis,⁵ nosocomial infection and mortality,⁶ and delayed initiation of breastfeeding of term newborns,⁷ as well as asthma and obesity later in life.^{8–10}

The main challenge with NICU antibiotic prescribing is that the decision to start antibiotics largely depends on a clinician's interpretation of a clinical situation and laboratory parameters of limited significance in the context of a still unproven infection.^{11,12} Culture-positive sepsis is rare, with so-called culture-negative sepsis being reported to be 6–16 times higher.¹³ Culture-negative sepsis is a poorly defined and overdiagnosed condition, with numerous noninfectious conditions that mimic sepsis being far more common.²

Great variability has been observed in antibiotic prescribing NICUs with similar burden of proven infection, mortality, and other parameters¹⁴; the widest variation—31-fold in one study—has been observed among intermediate-level NICUs in the United States.¹⁴ The recent AENEAS study (Antibiotic Exposure for Suspected Neonatal Early-onset Sepsis) showed that the proportion of neonates started on antibiotics ranged from 1.18% to 12.45% among 13 hospital networks in Europe, North America, and Australia for the period 2014–2018.¹⁵ The AENAES study group proposed seven key indicators for reporting data on early-onset sepsis (EOS) and antibiotic use: (1) incidence of culture-proven EOS per 1000 live births, (2) EOS-associated mortality rate, (3) proportion of neonates started on antibiotics per 100 live births, (4) duration of antibiotic therapy, and (5) number of antibiotic days per 1000 live births, and description of the study by (6) gestational age and (7) all-cause mortality.

While NICU antibiotic use seems to decline, thanks to stewardship programs,^{16,17} more needs to be done. It is not known, if an integrative medicine approach, that is, the integration of complementary and conventional medicine, leads to lower NICU antibiotic prescribing. It has been shown that physicians trained in complementary medicine have lower antibiotic prescribing, including for children.^{18–21} This lower prescribing appears to be related to complementary medicine approaches to health, which focus on self-regulation and rebalancing within the organism, and the potential effectiveness of certain medications from complementary medicine for infectious and noninfectious diseases.¹⁹

Various complementary medicine approaches have been integrated and studied in NICU settings, including music therapy, massage therapy, osteopathy, acupuncture, and aromatherapy.^{22–26} In addition, two NICUs in Germany integrate a full range of both pharmacologic and non-pharmacologic complementary medicine interventions from anthroposophic medicine.²⁷ One of them is at the Filderlinik, an anthroposophic, integrative medicine hospital in Southern Germany. The Filderlinik pediatric department

has a long-standing practice of restrictive antibiotic use, which we previously confirmed for childhood community-acquired pneumonia.²¹

The aim of this retrospective study was to (1) identify antibiotic use and compare this to local and international data, (2) compare differences in morbidity and outcomes in neonates with infection, managed with and without antibiotics, and (3) describe the use of complementary medicinal products, as well as possible observed side effects.

Methods

Study setting and population: A level-2 NICU in Filderstadt, in the South-Western state of Baden-Württemberg, Germany. In Germany, a level-2 perinatal center is defined as accepting neonates with an expected birth weight of >1250 g and >29 weeks gestational age and children of mothers with severe pregnancy-related disorders.²⁸

Study procedure: We searched retrospectively all NICU admissions of age 0 to 1 month from January 1, 2014, to December 31, 2017. We further identified neonates who had an infectious disease diagnosis in their discharge letter. Infectious disease was defined as any ICD-10 diagnosis related to infections specific to the perinatal period (P35 congenital viral diseases; P36 bacterial sepsis of newborn; P37 other congenital infectious and parasitic diseases; P38 omphalitis of newborn; and P39 other infections specific to the perinatal period); congenital pneumonia (P23); and neonatal aspiration (P24).

We conducted a detailed retrospective analysis of hospital medical records for all neonates with infectious disease diagnosis, dividing them into neonates having received systemic antibiotic therapy and those who did not. In addition to clinical and laboratory parameters, we extracted use of complementary medicinal products (only products given internally) and reviewed the medical records for notes on side effects or adverse reactions for any medication.

Culture-proven infection was defined by positive blood and/or cerebrospinal fluid (CSF) culture. Contaminated cultures were defined by growth of bacteria usually considered contaminants with a decision to treat with antibiotics for less than 5 days; cultures with growth of coagulase-negative staphylococci and antibiotic therapy for more than 5 days were considered proven infection.¹⁵

The antibiotic exposure was calculated in several ways: (1) proportion of neonates started on antibiotics per 100 live births, (2) duration of antibiotic therapy, (3) number of antibiotic days per 1000 live births, and (4) antibiotic use rate for all NICU admissions as number of antibiotic treatment days per 100 hospital days.²⁹

A subgroup analysis on antibiotic exposure was conducted to make our data set directly comparable to the AENEAS study.¹⁵ For this purpose, the antibiotic exposure was analyzed considering only infants born at a minimum gestational age of 34 weeks.

The federal state's quality assurance agency, Qualitätssicherung im Gesundheitswesen Baden-Württemberg

GmbH, was contacted to obtain comparative data of the Filderklinik NICU with all level-2 NICUs in the same state of Baden-Württemberg in terms of patient demographics, morbidity, and antibiotic use.

Data analysis: The programming language R (R version 4.1.2)³⁰ along with RStudio (Version 2021.09.1)³¹ was used to conduct all statistical analyses. The baseline values are expressed as descriptive statistics in absolute and relative frequency for categorical and binary variables. The median and interquartile range (IQR) is also included in the descriptive statistics for continuous variables. In addition to the descriptive statistics, comparison of continuous variables between antibiotic and no antibiotic was analyzed using Wilcoxon rank sum test and reported as median differences, 95% confidence interval (CI), *p*-value, and effect size “*r*.”³² Categorical variable comparison between antibiotic and no antibiotic was analyzed using the chi-square test and the *p*-value is reported.

The study was registered at clinicaltrials.gov with the identifier. The study was conducted according to the guidelines of the Declaration of Helsinki, was approved by the Ethics Committee of the University of Tübingen, Germany, and is reported here according to the STROBE-NI Statement.³³ Patient consent was not applicable due to the retrospective and anonymized nature of the study.

Results

From 2014 to 2017, 7778 children were born at the Filderklinik and 1086 neonates were hospitalized in the NICU. Of these neonates, 246 had an ICD-10 infectious disease diagnosis (suspected or confirmed) at discharge. The majority, 176 (71.5%) neonates, were treated with intravenous antibiotics, and 70 (28.5%) were managed without antibiotics (Fig. 1 Flow Diagram).

Maternal, delivery, and birth parameters: Among the 246 neonates with infectious disease diagnosis, 36.6% were females, the median gestational age was 40.29 weeks (IQR 1.46, range 29–42), and 3.25% had a low birth weight (<2500 g). Other than a slightly higher gestational age in the antibiotic treatment group, there was no significant difference of maternal, delivery, and birth parameters between the two groups of neonates (Tables 1 and 2).

Status of neonates at the time of admission and infectious disease parameters during hospitalization: The median age at admission was 0 days. Neonates in the antibiotic (AB) group were more likely to have fever, and had a slightly lower oxygen saturation and a higher C-reactive protein (CRP) value (Table 3). However, even in the no-antibiotic

(NAB) group, CRP values of up to 38 mg/L at admission were recorded. The maximum neutrophil count over the time of hospitalization, but not the initial neutrophil count, was higher in the AB group.

A total of 121 blood cultures were drawn; among neonates exposed to antibiotics, 60% had a blood culture drawn. Positive blood cultures included group B streptococci (2), methicillin-resistant *Staphylococcus aureus* (2), and different coagulase-negative cocci (10); 8 of these were considered contamination and treated for less than 5 days and 2 treated for more than 5 days and thus considered proven infection. All CSF and urine cultures were negative. The number of culture-proven infection therefore was 6 (0.77 per 1000 live births).

Treatment of neonates: The proportion of neonates started on antibiotics per 100 live births was 2.26% (176 treated neonates for 7778 live births). There were 866 antibiotic treatment days for a total of 9817 hospital days (counting all NICU admissions), resulting in an antibiotic use rate of 8.8 antibiotic days per 100 hospital days. The number of antibiotic days per 1000 live births was 111.

The median antibiotic treatment duration was 4.0 days (IQR: 2.0) and the most common antibiotic treatment duration was 5–6 days (56.8%); 28.4% were treated for 2–4 days (Table 4). The most commonly used antibiotics were a combination of ampicillin and gentamicin (received by >96% of neonates in the AB group). No significant difference in the number of neonates receiving continuous positive airway pressure (CPAP) was observed between the AB and NAB group. Mechanical ventilation was used in 7 neonates in the AB and 1 neonate in the NAB group.

Outcomes and discharge diagnoses: The hospitalization duration was twice as long in the AB group (6.0 days, IQR 3.0) (Table 4). No death occurred in either group. The five most common ICD-10 infectious disease diagnoses were bacterial sepsis of newborn (P36.9, 39.8%), infection specific to the neonatal period (P39.9, 25.2%), other bacterial sepsis of newborn (P36.8, 7.72%), congenital pneumonia (P23.9, 4.9%), and neonatal aspiration of meconium (P24.0, 4.5%) (see Supplementary Table S1 for full list of diagnoses).

Use of complementary medicinal products: Neonates in both the AB and the NAB group frequently received complementary medicinal products (Supplementary Table S2). Indications for prescription were generally not noted in medical records, but the range of products used indicates prescriptions for both infectious and noninfectious indications. Overall, 71 different natural substances were used in different preparations and dilutions. Route of administration included oral, inhalation, and intravenous (Supplementary Table S3). No side effect or adverse reaction was documented for neither conventional nor complementary medicinal products.

For the subanalysis to make the data comparable to the AENEAS study,¹⁵ we excluded 99 live births before 34 weeks of gestation and restricted analysis to neonates hospitalized within the first 7 days of life, thus presumably having started antibiotics in the first week of life. There were 7677 live births of minimum 34 weeks of gestation and 160 neonates treated with antibiotics, resulting in 2.08% of all live births in the Filderklinik exposed to antibiotics. With 2 positive cultures for group B streptococci, 1 methicillin-




FIG. 1. Flow diagram.

TABLE 1. MATERNAL AND DELIVERY PARAMETERS

		Total [N=246]	Antibiotic [n=176]	NAB [n=70]	Test statistics ^a
Birth	Spontaneous	138 (56.10%)	99 (56.25%)	39 (55.71%)	$p=0.498$
	Cesarean section	57 (23.17%)	38 (21.59%)	19 (27.14%)	
	Vacuum extraction/ forceps delivery	48 (19.51%)	37 (21.02%)	11 (15.71%)	
Gestational diabetes	Yes	18 (7.32%)	14 (7.95%)	4 (5.71%)	$p=0.736$
New-onset hypertension during pregnancy	Yes	4 (1.63%)	4 (2.27%)	0 (0.00%)	$p=0.476$
Group B streptococcal screening	Positive	39 (15.85%)	33 (18.75%)	6 (8.57%)	$p=0.219$
Rupture of membranes (hours before delivery) ^b	Median (IQR)	6.00 [16.00]	6.00 [16.00]	6.00 [11.50]	0.00 (-1.50; 2.00) $p=0.685$; $r=0.03$
Prolonged rupture of membranes	≥24 h	33 (13.41%)	22 (12.50%)	11 (15.71%)	
Maternal infection (any)	Present	2 (0.81%)	1 (0.57%)	1 (1.43%)	$p=1.000$
Intrapartum antibiotics	Received	26 (10.57%)	17 (9.66%)	9 (12.86%)	$p=0.613$
Amniotic fluid	Clear	144 (58.54%)	108 (61.36%)	36 (51.43%)	$p=0.473$
	Light green/green	54 (21.95%)	37 (21.02%)	17 (24.29%)	
	Thick/green brown	24 (9.76%)	15 (8.52%)	9 (12.86%)	
	Bloody	2 (0.81%)	1 (0.57%)	1 (1.43%)	
Chorioamnionitis	Yes	7 (2.85%)	6 (3.41%)	1 (1.43%)	$p=0.676$

^aWilcoxon rank sum test performed and reported as median differences, 95% CI, p -value, and effect size “ r ” for “Continuous variables.” Otherwise, chi-square test performed and p -value reported.

^bContentious variable; median and IQR is reported. Otherwise, absolute along with relative frequency reported. CI, confidence interval; IQR, interquartile range; NAB, no antibiotic.

TABLE 2. NEONATES AT BIRTH

		Total [N=246]	Antibiotic [n=176]	NAB [n=70]	Test statistics ^a
Twin pregnancy		8 (3.25%)	6 (3.41%)	2 (2.86%)	$p=1.000$
Gender	Female	90 (36.59%)	65 (36.93%)	25 (35.71%)	$p=0.974$
Gestational age (full weeks+days) ^b	Median (IQR)	40.29 [1.46]	40.57 [1.50]	40.00 [1.57]	-0.57 (-0.86; -0.14) $p=0.002$; $r=0.20$
Birthweight (gram) ^b	Median (IQR)	3560.00 [705.00]	3620.00 [687.50]	3490.00 [725.00]	-130.00 (-240.00; 65.00) $p=0.266$; $r=0.07$
Low birthweight	Birthweight ≥2500 g	236 (95.93%)	168 (95.45%)	68 (97.14%)	$p=0.479$
	Low birthweight <2500 g	8 (3.25%)	7 (3.98%)	1 (1.43%)	
	Very low birthweight <1500 g	2 (0.81%)	1 (0.57%)	1 (1.43%)	
Apgar at 1 min	10	16 (6.50%)	12 (6.82%)	4 (5.71%)	$p=0.367$
	9	121 (49.19%)	91 (51.70%)	30 (42.86%)	
	8	37 (15.04%)	23 (13.07%)	14 (20.00%)	
	4-7	52 (21.14%)	35 (19.89%)	17 (24.29%)	
	0-3	9 (3.66%)	8 (4.55%)	1 (1.43%)	
Apgar at 5 min	10	137 (55.69%)	100 (56.82%)	37 (52.86%)	$p=0.493$
	9	54 (21.95%)	34 (19.32%)	20 (28.57%)	
	8	28 (11.38%)	21 (11.93%)	7 (10.00%)	
	4-7	20 (8.13%)	16 (9.09%)	4 (5.71%)	
	0-3	2 (0.81%)	1 (0.57%)	1 (1.43%)	
pH, umbilical artery ^b	Median (IQR)	7.21 [0.14]	7.20 [0.15]	7.21 [0.12]	0.01 (-0.01; 0.04) $p=0.314$; $r=0.06$
Base excess, umbilical artery ^b	Median (IQR)	-7.00 [5.95]	-7.10 [6.25]	-6.20 [5.00]	0.90 (-0.40; 2.10) $p=0.186$; $r=0.08$

^aWilcoxon rank sum test performed and reported as median differences, 95% CI, p -value, and effect size “ r .” Otherwise, Chi-square test performed and p -value reported.

^bContentious variable; median and IQR is reported. Otherwise, absolute along with relative frequency reported.

TABLE 3. STATUS OF NEONATES AT THE TIME OF ADMISSION

		Total [N=246]	Antibiotic [n=176]	NAB [n=70]	Test statistics ^a
Age on admission (days) ^b	Median (IQR)	0.00 [1.00]	0.00 [1.00]	0.00 [1.00]	0.00 (-0.00;0.00) p=0.131; r=0.10
Temperature (C°) ^b	Median (IQR)	37.10 [0.90]	37.20 [0.98]	37.00 [0.70]	-0.20 (-0.40;0.00) p=0.055; r=0.12
Fever on admission (>38.0°C°)	Present	24 (9.76%)	22 (12.50%)	2 (2.86%)	p=0.040
Heart rate (per minute) ^b	Median (IQR)	130.00 [25.50]	132.00 [25.25]	124.50 [22.75]	-7.50 (-12.00; -0.00) p=0.042; r=0.13
Respiratory rate (per minute) ^b	Median (IQR)	53.00 [21.00]	56.00 [22.00]	48.00 [18.50]	-8.00 (-10.00;0.00) p=0.064; r=0.12
O ₂ Saturation (%) ^b	Median (IQR)	97.00 [5.00]	97.00 [5.00]	98.00 [3.75]	1.00 (0.00;2.00) p=0.001; r=0.20
Abnormal skin color	Abnormal	61 (24.80%)	50 (28.41%)	11 (15.71%)	p=0.113
Prolonged capillary refill time	>2 sec	95 (38.62%)	72 (40.91%)	23 (32.86%)	
Heart murmur	Absence documented	219 (89.02%)	157 (89.20%)	62 (88.57%)	p=1.000
	Present	15 (6.10%)	11 (6.25%)	4 (5.71%)	
Lung auscultation	Normal lung auscultation	198 (80.49%)	142 (80.68%)	56 (80.00%)	p=0.360
	Crackles	18 (7.32%)	13 (7.39%)	5 (7.14%)	
	Reduced breath sounds bilaterally	7 (2.85%)	6 (3.41%)	1 (1.43%)	
	Increased transmission of breath sounds	5 (2.03%)	2 (1.14%)	3 (4.29%)	
	Asymmetric breath sounds	3 (1.22%)	3 (1.70%)	0 (0.00%)	
Abdominal examination	Normal abdominal auscultation and palpation	211 (85.77%)	151 (85.79%)	60 (85.71%)	p=0.916
	Distended	7 (2.85%)	5 (2.84%)	2 (2.86%)	
	Sparse bowel sounds	2 (0.81%)	1 (0.57%)	1 (1.43%)	
CRP (mg/L; on admission) ^b	Median (IQR)	7.0 [22.2]	8.7 [27.5]	4.0 [14.3]	-4.7 (-6.8; -0.00) p=0.006; r=0.17
CRP (mg/L; max. during hospitalization) ^b	Median (IQR)	21.8 [29.5]	28.8 [29.1]	10.5 [16.6]	-18.3 (-23.1; -13.8) p<0.0001; r=0.45
Neutrophil count (10 ⁹ /L; on admission) ^b	Median (IQR)	65.70 [16.83]	66.10 [18.00]	64.70 [10.20]	-1.40 (-4.90;2.40) p=0.496; r=0.04
Neutrophil count (10 ⁹ /L; max. during hospitalization) ^b	Median (IQR)	69.45 [15.00]	71.70 [14.80]	66.60 [13.60]	-5.10 (-8.60; -2.00) p=0.002; r=0.20
Leukocyte count (10 ⁹ /L; on admission) ^b	Median (IQR)	16.10 [9.30]	15.85 [10.07]	17.50 [7.70]	1.65 (-1.40;2.40) p=0.620; r=0.03
Leukocyte count (10 ⁹ /L; max. during hospitalization) ^b	Median (IQR)	18.40 [8.62]	19.20 [8.25]	17.90 [8.60]	-1.30 (-2.90;0.40) p=0.157; r=0.09

(continued)

TABLE 3. (CONTINUED)

	Total [N = 246]	Antibiotic [n = 176]	NAB [n = 70]	Test statistics ^a
Blood culture	106 (43.09%)	88 (50.00%)	18 (25.71%)	$p = 0.738$
No growth	2 (0.81%)	2 (1.14%)	0 (0.00%)	
Group B streptococci	2 (0.81%)	2 (1.14%)	0 (0.00%)	
<i>Staphylococcus aureus</i> (MRSA type)	2 (0.81%)	1 (0.57%)	1 (1.43%)	
<i>Staphylococcus epidermidis</i>	4 (1.63%)	3 (1.70%)	1 (1.43%)	
<i>Staphylococcus hominis</i>	1 (0.41%)	1 (0.57%)	0 (0.00%)	
<i>Staphylococcus auricularis</i>	1 (0.41%)	1 (0.57%)	0 (0.00%)	
<i>Staphylococcus capitis</i>	3 (1.22%)	3 (1.70%)	0 (0.00%)	
No growth	0 (0.00%)	0 (0.00%)	0 (0.00%)	$p = 0.083$
Positive	4 (1.63%)	4 (2.27%)	0 (0.00%)	NA
No growth	1 (0.41%)	1 (0.57%)	0 (0.00%)	NA
Positive	6 (2.44%)	6 (3.41%)	0 (0.00%)	$p = 0.014$
No abnormal growth				
Cerebrospinal fluid culture				
Urine culture				
Stool culture				

^aWilcoxon rank sum test performed and reported as median differences, 95% CI, p -value, and effect size “ r .” Otherwise, chi-square test performed and p -value reported.

^bContentious variable; median and interquartile range is reported. Otherwise, absolute along with relative frequency reported.

CRP, C-reactive protein.

resistant *S. aureus*, and 8 coagulase-negative cocci treated for less than 5 days and 2 treated for more than 5 days, the number of culture-proven EOS was 5 and the incidence of culture-proven EOS per 1000 live births was 0.65. The number of antibiotic days was 772, resulting in 100 antibiotic days per 1000 live births.

According to reports received by the state’s quality assurance agency, Qualitätssicherung im Gesundheitswesen Baden-Württemberg GmbH, 14.3% (CI: 12.3–6.5) of neonates hospitalized at the Filderklinik NICU were exposed to antibiotics between 2014 and 2017 compared to 30.9% (CI: 29.8–32.1) across all level-2 NICUs in the same German state of Baden-Württemberg (personal communication with Qualitätssicherung im Gesundheitswesen Baden-Württemberg GmbH). Unfortunately, it was not possible to obtain additional information about the other level-2 NICUs to assess if patient populations were comparable in terms of demographics and morbidity or to calculate the antibiotic use rate across these centers.

Limitations

A number of limitations apply to this study due to its retrospective design. Infectious disease cases and antibiotic treatment courses were identified through infectious disease discharge diagnoses. Discharge diagnosis coding has been shown as reliable for common infections in adults,³⁴ but there could have been a bias toward overdiagnosis because of the diagnosis-related group billing system. Such bias could have lowered the antibiotic use rate among the hospitalized neonates, but not the proportion of neonates started on antibiotics per live births. Possible overdiagnosis makes it unlikely that antibiotic treatment courses would have been missed in our analysis.

The more specific coding might also have been biased: The majority (55.1%) in the AB group was coded as neonatal sepsis (ICD-10 P36.9), while the majority in the NAB group (67.1%) was coded as infection specific to the neonatal period (ICD-10 P39.9). These coding decisions were probably influenced by the treatment, that is, infections were more likely coded as neonatal sepsis when antibiotics were used and coded as unspecified neonatal infection when antibiotics were not used. This bias had no influence on the group categorization and thus the outcomes of this study.

Other limitations linked to the retrospective design are possible missing data. For example, relevant clinical clues that guided clinicians to prescribe or withhold antibiotics may not have been documented. Not all neonates started on antibiotics had blood cultures drawn, resulting in a possible underdiagnosis of culture-proven sepsis.

The comparison with other level-2 NICUs in the same state was limited because patient demographics and morbidity could not be obtained for the other NICUs and data allowed only to compare the frequency of antibiotic prescription (prescription courses per 100 NICU admissions).

Discussion

In this cohort of neonates from a hospital practicing an integrative medicine approach, the exposure to antibiotics was very low in international comparison. The antibiotic exposure in 13 networks in Europe, North America, and Australia, as reported by the AENEAS study, ranged from

TABLE 4. NEONATE TREATMENT

		Total [N=246]	Antibiotic [n=176]	NAB [n=70]	Test statistics ^a
Antibiotic therapy duration	<48 h	4 (1.63%)	4 (2.27%)		NA
	2–4 days	50 (20.33%)	50 (28.41%)		
	5–6 days	100 (40.65%)	100 (56.82%)		
	≥7 days	18 (7.32%)	18 (10.23%)		
Ampicillin	Received	170 (69.11%)	170 (96.59%)		NA
Gentamicin	Received	169 (68.70%)	169 (96.02%)		NA
Cefotaxime	Received	5 (2.03%)	5 (2.84%)		NA
Flucoxacillin	Received	2 (0.81%)	2 (1.14%)		NA
Cefuroxime	Received	1 (0.41%)	1 (0.57%)		NA
Continuous positive airway pressure CPAP	Received	52 (21.14%)	41 (23.30%)	11 (15.71%)	$p=0.222$
Mechanical ventilation	Received	8 (3.25%)	7 (3.98%)	1 (1.43%)	$p=0.523$
Hospitalization (days) ^b	Median (IQR)	6.00 [3.00]	6.00 [3.00]	3.00 [3.00]	$-3.00 (-4.00; -2.00)$ $p < 0.0001; r = 0.52$

^aWilcoxon rank sum test performed and reported as median differences, 95% CI, p -value, and effect size “ r .” Otherwise, chi-square test performed and p -value reported.

^bContentious variable; median and interquartile range is reported. Otherwise, absolute along with relative frequency reported.

1.18% to 12.45% of neonates per 1000 live births,¹⁵ while the Filderlinik exposure was 2.08% when using the same inclusion criteria. The disease burden of 0.65 EOS cases per 1000 live births was in the mid-range when compared to the range of 0.18–1.45 in the AENEAS study.

The antibiotic use rate (antibiotic days/hospital days) of 8.8% had no comparator in the AENEAS study, but was in the low range when compared to a cross-sectional survey in the United States, which found a highly variable antibiotic use rate ranging from 2.4% to 97.1% (median 24.5%).²⁹ Antibiotic use of the Filderlinik NICU was also low in local comparison with 14.3% of hospitalized neonates receiving an antibiotic treatment course compared to an average 30.9% across all level-2 NICUs in the same state in Germany.

With a median age of 0 days at admission, the vast majority of neonates had suspected early-onset neonatal infections, including EOS. Our analysis found that 28.5% (70 out of 246) of neonates with a suspected infectious disease were managed without antibiotics. This does not mean that true neonatal infections can be managed without antibiotics; it simply shows that in a number of situations of suspected infection, careful monitoring without antibiotics is possible.

Vice versa, we do not know from this retrospective analysis if antibiotics were truly needed in all cases in the AB group—with 29 neonates treated per culture-positive sepsis and culture-negative sepsis being a poorly defined entity, there remains substantial overtreatment, as is true for all NICUs.² Not surprisingly, neonates started on antibiotics were slightly sicker in terms of clinical appearance, laboratory parameters, and need for respiratory support than those who managed without. Nevertheless, the NAB group also included children with abnormal clinical and laboratory parameters and in need of respiratory assistance.

There were two lessons learnt for the Filderlinik NICU from this study. First, blood cultures need to be drawn in all neonates with suspected infection. Second, the most common antibiotic treatment duration was 5–6 days. The number of antibiotic days could be further reduced by implementing 48-h treatment courses for rule-out sepsis situations, and 5 days for culture-negative pneumonia and culture-negative sepsis.^{35–37}

To our knowledge, this is the first report of antibiotic use in an NICU practicing integrative medicine. A large variety of complementary medicinal products from natural substances were used in both the AB and NAB group, in safe dilutions of 1:100 or higher in almost all cases. Neither the benefit of these complementary medicinal products nor their impact on antibiotic treatment decisions can be assessed from this study.

While benefit is possible, it should be noted that some networks such as in Stockholm, Sweden,¹⁵ had lower antibiotic use than this network and without resorting to complementary medicine. The lack of documented side effects or adverse reactions is reassuring. Regardless of any proven effect of complementary medicinal products, physicians trained in complementary medicine are known to be more restrictive in antibiotic prescribing, including hospitalized children,²¹ putting more emphasis on reinforcing natural healing capacity.¹⁹ Therefore, the hypothesis that complementary therapies—in addition to other antimicrobial stewardship programs—can contribute to decrease the burden of antibiotic treatment in neonates should be further explored.

Conclusions

Antibiotic use was low in this integrative medicine NICU in both local and international comparison, confirming an association, but no causality between integrative medicine practice and low antibiotic prescription in newborns. Complementary medicinal products were widely used for infectious and noninfectious indications and well tolerated. Future prospective studies should test whether or not the lower exposure to antibiotics presented in this study can be attributed to the additional use of complementary medicinal products.

Acknowledgments

The authors thank Bernard Deckers, R.N., and Christian Jeske, R.N., for data extractions from patient files, and Dr. Dieter Ecker, who was the responsible attending

pediatrician/neonatologist for the Filderklinik NICU during the time period analyzed in this study.

Authors' Contributions

Conceptualization and methodology, J.V., B.H., and T.v.S.-A.; software, M.O.A.I.; validation, M.O.A.I. and J.V.; formal analysis, M.O.A.I. and J.V.; investigation, J.V. and B.H.; data curation, M.O.A.I.; writing—original draft preparation, T.v.S.-A.; writing—review and editing, all authors. All authors have read and agreed to the published version of the article.

Data Availability Statement

Raw data are available through the OSF Registry at <https://osf.io/b8etw/>

Author Disclosure Statement

No competing financial interests exist.

Funding Information

The ARCIM Institute receives nonrestricted funding from the Mahle Foundation, Germany. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the article; or in the decision to publish the results.

Supplementary Materials

Supplementary Table S1
Supplementary Table S2
Supplementary Table S3

References

- Folgori L, Ellis SJ, Bielicki JA, et al. Tackling antimicrobial resistance in neonatal sepsis. *Lancet Global Health* 2017;5(11):e1066–e1068; doi: [https://doi.org/10.1016/S2214-109X\(17\)30362-5](https://doi.org/10.1016/S2214-109X(17)30362-5)
- Stocker M, Klingenberg C, Navér L, et al. Less is more: Antibiotics at the beginning of life. *Nat Commun* 2023; 14(1):2423.
- Alexander VN, Northrup V, Bizzarro MJ. Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. *J Pediatr* 2011;159(3):392–397.
- Cantey JB, Huffman LW, Subramanian A, et al. Antibiotic exposure and risk for death or bronchopulmonary dysplasia in very low birth weight infants. *J Pediatr* 2017;181:289–293. e1
- Cotten CM, McDonald S, Stoll B, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. *Pediatrics* 2006; 118(2):717–722.
- Kuppala VS, Meinzen-Derr J, Morrow AL, et al. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. *J Pediatr* 2011;159(5): 720–725.
- Mukhopadhyay S, Lieberman ES, Puopolo KM, et al. Effect of early-onset sepsis evaluations on in-hospital breastfeeding practices among asymptomatic term neonates. *Hosp Pediatr* 2015;5(4):203–210.
- Alm B, Erdes L, Möllborg P, et al. Neonatal antibiotic treatment is a risk factor for early wheezing. *Pediatrics* 2008;121(4):697–702.
- Vangay P, Ward T, Gerber Jeffrey S, et al. Antibiotics, pediatric dysbiosis, and disease. *Cell Host Microbe* 2015; 17(5):553–564; doi: <http://dx.doi.org/10.1016/j.chom.2015.04.006>
- Saari A, Virta LJ, Sankilampi U, et al. Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. *Pediatrics* 2015;135(4):617–626.
- Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. *Lancet* 2017;390(10104):1770–1780; doi: [https://doi.org/10.1016/S0140-6736\(17\)31002-4](https://doi.org/10.1016/S0140-6736(17)31002-4)
- Stocker M, Giannoni E. Game-changer or gimmick: Inflammatory markers to guide antibiotic treatment decisions in neonatal early-onset sepsis. *Clin Microbiol Infect* 2023.
- Klingenberg C, Kornelisse RF, Buonocore G, et al. Culture-negative early-onset neonatal sepsis—At the crossroad between efficient sepsis care and antimicrobial stewardship. *Front Pediatr* 2018;6:285.
- Schulman J, Dimand RJ, Lee HC, et al. Neonatal intensive care unit antibiotic use. *Pediatrics* 2015;135(5):826–833.
- Giannoni E, Dimopoulou V, Klingenberg C, et al. Analysis of antibiotic exposure and early-onset neonatal sepsis in Europe, North America, and Australia. *JAMA Netw Open* 2022;5(11):e2243691–e2243691.
- Araujo da Silva AR, Marques A, Di Biase C, et al. Effectiveness of antimicrobial stewardship programmes in neonatology: A systematic review. *Arch Dis Child* 2020; 105(6):563–568; doi: 10.1136/archdischild-2019-318026
- Spencer HJJ, Dantuluri KL, Thurm C, et al. Variation in antibiotic use among neonatal intensive care units in the United States. *Infect Control Hosp Epidemiol* 2022;43(12): 1945–1947; doi: 10.1017/ice.2021.379
- van der Werf ET, Duncan LJ, Flotow Pv, et al. Do NHS GP surgeries employing GPs additionally trained in integrative or complementary medicine have lower antibiotic prescribing rates? Retrospective cross-sectional analysis of national primary care prescribing data in England in 2016. *BMJ Open* 2018;8(3):e020488; doi: 10.1136/bmjopen-2017-020488
- Baars EW, Zoen EB, Breikreuz T, et al. The contribution of complementary and alternative medicine to reduce antibiotic use: A narrative review of health concepts, prevention, and treatment strategies. *Evid Based Complement Alternat Med* 2019;2019:5365608; doi: 10.1155/2019/5365608
- Hamre HJ, Glockmann A, Schwarz R, et al. Antibiotic use in children with acute respiratory or ear infections: Prospective observational comparison of anthroposophic and conventional treatment under routine primary care conditions. *Evid Based Complement Alternat Med* 2014;2014: 243801; doi: 10.1155/2014/243801
- Vagedes J, Martin D, Müller V, et al. Restrictive antibiotic use in children hospitalized for pneumonia: A retrospective inpatient study. *Eur J Integr Med* 2020;34:101068; doi: <https://doi.org/10.1016/j.eujim.2020.101068>
- Bieleninik Ł, Ghetti C, Gold C. Music therapy for preterm infants and their parents: A meta-analysis. *Pediatrics* 2016; 138(3):e20160971.
- Ebrahimi HK, Jafarnejad S, Esmaeilian S, et al. Examining the effect of massage on preterm infants' pain caused by invasive procedures in neonatal intensive care unit. *J Complement Med Res* 2020;11(3):99–105.

24. Cicchitti L, Di Lelio A, Barlafante G, et al. Osteopathic manipulative treatment in neonatal intensive care units. *Med Sci* 2020;8(2):24.
25. Chen K, Quah-Smith I, Schmölzer G, et al. Acupuncture in the neonatal intensive care unit—Using ancient medicine to help today’s babies: A review. *J Perinatol* 2017;37(7):749–756.
26. Usta C, Tanyeri-Bayraktar B, Bayraktar S. Pain control with lavender oil in premature infants: A double-blind randomized controlled study. *J Alternat Complement Med* 2021;27(2):136–141.
27. Kienle GS, Albonico H-U, Baars E, et al. Anthroposophic medicine: An integrative medical system originating in Europe. *Global Adv Health Med* 2013;2(6):20–31; doi: <https://doi.org/10.7453/gahmj.2012.087>
28. Guideline of the Federal Joint Committee on Measures to Ensure the Quality of Care for Pregnant and Mature Babies. *Bundesanzeiger* 2021;AT 17.11.2021 B4.
29. Schulman J, Profit J, Lee HC, et al. Variations in neonatal antibiotic use. *Pediatrics* 2018;142(3):e20180115; doi: 10.1542/peds.2018-0115
30. RCore TEAM. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria; 2021.
31. Allaire J. RStudio: Integrated Development Environment for R. Boston, MA; 2012, Vol. 770(394); pp. 165–171.
32. Fritz CO, Morris PE, Richler JJ. Effect size estimates: Current use, calculations, and interpretation. *J Exp Psychol Gen* 2012;141(1):2.
33. Fitchett EJA, Seale AC, Vergnano S, et al. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. *Lancet Infect Dis* 2016;16(10):e202–e213; doi: 10.1016/s1473-3099(16)30082-2
34. Wiese AD, Griffin MR, Stein CM, et al. Validation of discharge diagnosis codes to identify serious infections among middle age and older adults. *BMJ Open* 2018;8(6):e020857; doi: 10.1136/bmjopen-2017-020857
35. Cantey JB, Wozniak PS, Pruszynski JE, et al. Reducing unnecessary antibiotic use in the neonatal intensive care unit (SCOUT): A prospective interrupted time-series study. *Lancet Infect Dis* 2016;16(10):1178–1184; doi: [https://doi.org/10.1016/S1473-3099\(16\)30205-5](https://doi.org/10.1016/S1473-3099(16)30205-5)
36. Rooney AM, Timberlake K, Brown KA, et al. Each additional day of antibiotics is associated with lower gut anaerobes in neonatal intensive care unit patients. *Clin Infect Dis* 2019;70(12):2553–2560; doi: 10.1093/cid/ciz698
37. Kopsidas I, Tsopela G-C, Molocha N-M, et al. Reducing duration of antibiotic use for presumed neonatal early-onset sepsis in greek NICUs. A “Low-Hanging Fruit” approach. *Antibiotics* 2021;10(3):275.

Address correspondence to:
Tido von Schoen-Angerer, MD, MPH
ARCIM Institute
Filderstadt 70794
Germany

E-mail: tido.von.schoenangerer@gmail.com